REGENXBIO disclosed that on January 28, 2026, the U.S. Food and Drug Administration placed a full clinical hold on its intracisternal gene therapy candidate RGX-111 for MPS I (Hurler syndrome) and on RGX-121 for MPS II (Hunter syndrome). The action follows the detection of a single intraventricular CNS tumor in an asymptomatic five-year-old participant who received RGX-111 four years earlier. Genetic analysis of the resected lesion revealed AAV vector integration near the proto-oncogene PLAG1, raising safety concerns. To date, no neoplasms have been reported in the nine other RGX-111 subjects or in 32 patients dosed with RGX-121. The company has not yet received the full clinical hold letter and is awaiting detailed FDA feedback while continuing its ongoing investigations into causality and risk mitigation.

On the day of the announcement, RGNX shares experienced a dramatic uptick in trading activity, with 3.83 million shares changing hands versus the 90-day average daily volume of approximately 684,000. This represented a 460% increase in turnover, underscoring investor concern over the uncertain timeline for program resumption. Although the clinical hold relates to two rare-disease programs that together address fewer than 100 patients globally per year, the decision disrupts REGENXBIO’s near-term regulatory roadmap, including the pivotal RGX-121 Biologics License Application expected ahead of a February PDUFA date.

REGENXBIO’s balance sheet remains fortified with a cash runway extending into 2027, underpinned by recent partnerships and milestone payments from Nippon Shinyaku and AbbVie. However, delays to RGX-121’s approval could defer projected revenues in the mid-2020s and shift the timing of anticipated cell-and-gene therapy royalties. Management reiterated that patient safety is paramount and emphasized the robust safety and efficacy signals from RGX-121’s pivotal trial, including sustained reductions in CSF heparan sulfate biomarkers in more than 30 boys treated up to seven years ago. Investors will closely monitor the FDA’s forthcoming clinical hold letter for clarity on data requirements and potential protocol amendments.

Key catalysts over the next three to six months include the FDA’s formal clinical hold notice detailing the path to lifting restrictions, interim safety updates from REGENXBIO’s ongoing non-human primate studies, and progress on other pipeline assets such as RGX-202 for Duchenne muscular dystrophy. The company also expects to present updated durability and biomarker data at upcoming scientific conferences. Resolution of the hold could restore confidence in AAV9-based CNS delivery and re-accelerate the valuation multiple for this late-stage gene therapy platform.